Development
Ocular Therapeutix, Inc.
OCUL
$8.25
-$0.08-0.96%
NASDAQ
| 12/31/2023 | 09/30/2023 | ||||
|---|---|---|---|---|---|
| Revenue | -1.86% | -0.69% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -1.86% | -0.69% | |||
| Cost of Revenue | 7.23% | -0.01% | |||
| Gross Profit | -111.41% | -8.50% | |||
| SG&A Expenses | -3.51% | -7.54% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 1.62% | -4.09% | |||
| Operating Income | -4.35% | 6.59% | |||
| Income Before Tax | -5,562.79% | 97.51% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -5,562.79% | 97.51% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -5,562.79% | 97.51% | |||
| EBIT | -4.35% | 6.59% | |||
| EBITDA | -4.19% | 8.00% | |||
| EPS Basic | -5,224.62% | 97.55% | |||
| Normalized Basic EPS | -86.79% | 30.07% | |||
| EPS Diluted | -36.64% | 4.42% | |||
| Normalized Diluted EPS | -100.28% | 34.78% | |||
| Average Basic Shares Outstanding | 6.37% | 1.70% | |||
| Average Diluted Shares Outstanding | -0.84% | 9.09% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||